Trastuzumab & PertuzumabShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Sponsor:

Alliance for Clinical Trials in Oncology

Code:

NCT06876714

Conditions

Anatomic Stage I Breast Cancer AJCC v8

Anatomic Stage II Breast Cancer AJCC v8

Early Stage HER2+ Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Trastuzumab (Herceptin)

Pertuzumab

Echocardiography

Multigated Acquisition Scan

Mammography

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-21. This information was provided to ClinicalTrials.gov by Alliance for Clinical Trials in Oncology on 2026-08-05.